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Since 1990, the Human Genome Project and
subsequent technologic advances have made
generating genetic information cheaper, eas-
ier, and more reliable, thus changing the face
of science (Decaprio 1997). Recently devel-
oped technologies have enabled scientists to
identify mutations that define human vari-
ability, determine the prevalence of identiﬁed
genetic mutations in the population, and
interpret the function and role of specific
genes in disease. In May 2002, the U.S.
Environmental Protection Agency’s (EPA)
Science Policy Council released an Interim
Policy on Genomics (U.S. EPA 2002c). The
U.S. EPA continued to explore the applica-
tion of genomic information in a second doc-
ument, Potential Implications for Genomics for
Regulatory and Risk Assessment Applications at
EPA (U.S. EPA 2004b). The interim policy
heralds the potential of genomic information
“to enhance its assessments and better inform
the decision-making process.” Genomic
information has the potential to improve the
U.S. EPA’s regulatory process in a key con-
text—the setting of health-based standards
directed at protecting susceptible subpopula-
tions. The interim policy concludes that as
the U.S. EPA “gains experience in applying
genomics information . . . it will develop
guidance to explain how genomics data can
be better used in decision making, and related
ethical, legal, and social implications” (U.S.
EPA 2002c).
In this commentary we examine opportu-
nities within current policy for the inclusion of
genetic information in regulation of air pollu-
tants, with particular attention to particulate
matter (PM). We focus on key polymorphisms
that identify asthmatics, an established sensi-
tive subpopulation that stands to beneﬁt from
the inclusion of genetic information in air
quality regulation (U.S. Senate 1970). In a
subsequent analysis (Cullen AC, Kramer CB,
Faustman E, unpublished data) we extend the
integration of genomic science and regulatory
policy using a decision analytic framework. An
additional manuscript (Bradley A, Cullen A,
Burke W, Faustman E, unpublished data)
addresses both the importance and the chal-
lenge of incorporating genetic information in
other statutory contexts, such as food safety
and pesticides.
The U.S. Clean Air Act (CAA) requires
that the EPA set National Ambient Air
Quality Standards (NAAQS) for six criteria
pollutants: carbon monoxide, lead, nitrogen
dioxide, ozone, sulfur oxides, and PM. These
standards are set at levels “requisite to protect
public health” with “an adequate margin of
safety” [U.S. Clean Air Act Amendments
(CAAA) 1990 §109(b)(1)]. The CAA further
requires the U.S. EPA to consider sensitive
subpopulations and the increased risk they
bear as a result of exposure to criteria air pol-
lutants [U.S. Clean Air Act Amendments
1990 §108(f)(1)(C)]. Asthmatics represent a
significant and increasing subpopulation in
the United States (U.S. EPA 2003). Since the
Centers for Disease Control and Prevention
(CDC) began reporting on the occurrence of
asthma in 1980, the number of asthmatics in
the United States has been steadily rising. In
2002, the CDC reported that 30.8 million
people were clinically diagnosed with asthma
at some point over their lifetime (CDC 2005).
Asthma is a complex disease with environ-
mental and genetic contributions to both dis-
ease susceptibility and progression. Genomic
information can increase our understanding of
asthma etiology as well as individual and pop-
ulation predisposition to developing asthma.
Exposure to airborne PM exacerbates the
physiologic responses leading to asthma, such
as airway inﬂammation, and may also increase
sensitization to allergens resulting in atopy, a
risk factor associated with asthma (Dockery
et al. 1993; Pope et al. 1995). In an effort to
improve scientiﬁc understanding of the mech-
anisms governing the relationship between
asthma and PM exposure, government agen-
cies have developed targeted research strategies
[National Research Council (NRC) 1998,
1999, 2001, 2004; U.S. Department of
Health and Human Services (DHHS) 2000;
U.S. EPA 2002a] and directed substantial
funding to this goal. By measuring the preva-
lence of genetic biomarkers, scientists can
quantify the health risks borne by the most
susceptible subpopulations among asthmatics,
as a result of exposure to specific concentra-
tions of PM. These data can inform the air-
quality standard-setting process to protect
even the most sensitive individuals from
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The U.S. Clean Air Act (CAA) explicitly guarantees the protection of sensitive human subpopulations
from adverse health effects associated with air pollution exposure. Identiﬁed subpopulations, such as
asthmatics, may carry multiple genetic susceptibilities to disease onset and progression and thus qual-
ify for special protection under the CAA. Scientiﬁc advances accelerated as a result of the ground-
breaking Human Genome Project enable the quantiﬁcation of genetic information that underlies such
human variability in susceptibility and the cellular mechanisms of disease. In epidemiology and regu-
latory toxicology, genetic information can more clearly elucidate human susceptibility essential to risk
assessment, such as in support of air quality regulation. In an effort to encourage the incorporation of
genomic information in regulation, the U.S. Environmental Protection Agency (EPA) has issued an
Interim Policy on Genomics. Additional research strategy and policy documents from the National
Academy of Science, the U.S. EPA, and the U.S. Department of Health and Human Services further
promote the expansion of asthma genetics research for human health risk assessment. Through a
review of these government documents, we ﬁnd opportunities for the inclusion of genetic information
in the regulation of air pollutants. In addition, we identify sources of information in recent scientiﬁc
research on asthma genetics relevant to regulatory standard setting. We conclude with recommen-
dations on how to integrate these approaches for the improvement of regulatory health science and
the prerequisites for inclusion of genetic information in decision making. Key words: asthma,
Clean Air Act, genetics, particulate matter, risk analysis. Environ Health Perspect 114:313–319
(2006). doi:10.1289/ehp.8299 available via http://dx.doi.org/ [Online 26 October 2005]adverse health effects with an adequate margin
of safety.
Through a review of these government
documents we ﬁnd opportunities for the inclu-
sion of genetic information in the regulation of
air pollutants. In addition, we identify sources
of information in recent scientiﬁc research on
asthma genetics relevant to regulatory standard
setting. We conclude with recommendations
about integrating laboratory-based science, in
the form of genetic information, into the risk
management process to improve regulatory
decision making.
Materials and Methods
To analyze the potential role of genetic infor-
mation in PM regulation, we considered a
range of sources pertaining to the U.S. EPA’s
mandate. Initially, we reviewed the statutory
language of Title I of the 1990 (CAAA)—the
current, primary statute for setting air quality
standards (U.S. Clean Air Act Amendments
1990). Refinement of the statutory mandate
was obtained through a LexisNexis (2004)
search of federal court cases providing judiciary
clariﬁcation of the language and its application
to PM NAAQS. In addition, we examined two
key documents that deﬁne the U.S. EPA’s risk
assessment approach in standard setting and
the potential role of genomic information in
this process. The ﬁrst of these, the Air Quality
Criteria for Particulate Matter (U.S. EPA
2004a) issued by the U.S. EPA’s Office of
Research and Development, is intended to
“accurately reﬂect the latest scientiﬁc knowl-
edge useful in indicating the kind and extent of
identiﬁable effects on public health or welfare”
(U.S. Clean Air Act Amendments 1990; U.S.
EPA 2004a). The second of these documents,
the Office of Air Quality Planning and
Standards (OAQPS) staff paper, was prepared
by the U.S. EPA’s OAQPS after extensive peer
review and approval of the criteria document
(U.S. EPA 2003). The OAQPS staff paper rec-
ommends a national, population-speciﬁc stan-
dard(s) based on extensive risk assessment
scenarios for diverse urban centers across the
United States. We consulted the 2002 Interim
Policy on Genomics (U.S. EPA 2002c) to assess
the U.S. EPA’s anticipated expansion of its
efforts to incorporate genetic information in
decision making and risk assessment agency-
wide. We refer to the most current ﬁnal ver-
sion of the PM criteria document (U.S. EPA
2004a) and the recent draft PM staff paper
(U.S. EPA 2003), unless otherwise noted.
In addition, to evaluate recent progress on
asthma genetics research relevant to air pollution
risk assessment, we reviewed the current litera-
ture through a Medline (PubMed 2004) search
on asthma, genetics, and air pollution and resul-
tant references. We then developed and applied
criteria for prioritizing health science on genetic
susceptibility to asthma relevant to regulation.
We established these criteria on the basis of
review articles detailing current trends in link-
age, association, and candidate gene studies
(Bracken et al. 2002; Tabor et al. 2002). Using
these criteria and examination of review articles,
linkage analyses, and a genetic information data-
base, we culled six exemplary candidate genes
for further review [Borish 1999; Bracken et al.
2002; Collaborative Study on the Genetics of
Asthma 1997; Cookson 1999, 2002; Daniels
et al. 1996; Hakonarson and Wjst 2001; Huss
and Huss 2000; Online Mendelian Inheritance
in Man (OMIM) 2000; Sengler et al. 2002].
We assessed multiple association studies that
link asthma to single nucleotide polymorphisms
within these candidate genes. Finally, we
reviewed established government research strate-
gies and identified decision points at which
asthma and/or genetics are given priority.
Results
The CAA and genetic information. Title I of
the CAAA contains the current mandate for
setting regulatory standards on air pollution
(U.S. Clean Air Act Amendments 1990). In
Figure 1, we highlight key language deﬁning
the statutory requirement, with a focus on PM.
The left column outlines the research mandate
of section 103 encouraging the development of
the necessary health science data and collabora-
tion between agencies; the middle column cites
the statutory language pertaining to setting the
health-based NAAQS, including PM, under
sections 108 and 109; and the right column
details development of technology-based stan-
dards for hazardous air pollutants (HAPs),
many of which occur as PM, under section
112. In addition, the CAA requires a health-
based standard for HAPs, in contexts where
the technology-based standard proves insufﬁ-
cient to protect health. A health-based risk
assessment for a HAP includes methodologies
and results in conclusions also applicable to
PM NAAQS (Lippmann and Schlesinger
2000). Overall, we focus on speciﬁc statutory
language for criteria air pollution regulation,
and the speciﬁc decision points for which the
U.S. EPA’s Interim Policy on Genomics (U.S.
EPA 2002c) recommends the incorporation of
genomic information. Interpretations of “sensi-
tive subpopulations,” “adverse effect,” and
“risk assessment process,” shared by the CAA
and the Interim Policy on Genomics, are dis-
cussed in the following sections.
Sensitive subpopulations. The CAA
ensures regulation that will “protect the health
Kramer et al.
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Human health risk assessment
Assessment of “residual risk” at a future time
Maximally exposed individual
1/1,000,000 increased cancer [§112(c)(9)(B)(i)]
Clean Air Act—Title I
National research and development
Coordinate and accelerate research, investigations
Cooperate with public and private agencies, institutions
Conduct investigations and research
Establish technical advisory committees
Health Effects Institute (HEI)
National Environmental Respiratory Center (NERC)
PM research centers
Advisory commitees
Criteria pollutants “may reasonably be anticipated
to endanger public health or welfare”
(§108)
PM, SOx, NO2, CO2, O3 and lead
Human health risk assessment
Promulgate primary and secondary air quality
standards [§109(a)]
Primary: “adequate margin of safety” [§109(b)(1)]
“Sensitive or susceptible individuals or groups” from
“adverse effects” [§108(f)(1)(c)]
“All identifiable effects on public health” [§108(a)(2)]
Hazardous air pollutants
list of 189 established by Congress
[§112(b)]
Technology-based control standard
“Present a threat of adverse human health effects”
[§112(b)(2)]
Maximum achievable control technology (MACT)
Feasible on technical and economic grounds
National Ambient Air Quality Standard
PM10 50 µg/m3 150 µg/m3
PM2.5 15 µg/m3   65 µg/m3
Annual Daily
Research, investigation, training, and other activities (§103)
Figure 1. The CAA provisions for protection of human populations (Title I, U.S. Clean Air Act Amendments 1990). The CAA provides for protection of human health
through research (left), standard setting for criteria pollutants (middle), and standard list of 189 HAPs, established by Congress (right).of sensitive or susceptible individuals or
groups” [Clean Air Act Amendments 1990
§108(f)(1)(C)]. This mandate is interpreted by
the courts in several cases: Ober v. Whitman
(2001), American Lung Association v. EPA
(1998), and Lead Industries Association v. EPA
(1980). Each of the cases refers back to the
1970 senate report that led to the enactment of
the CAA to deﬁne susceptible subpopulations
(U.S. Senate 1970). The senate report states
that the CAA will address “particularly sensi-
tive citizens such as bronchial asthmatics and
emphysematics,” through the development of
“ambient standards necessary to protect . . .
sensitive group[s] rather than a single person in
such a group.” Additionally, the current PM
criteria document and PM staff paper name
children, the elderly, and those with preexist-
ing disease, such as chronic obstructive pul-
monary disease, emphysema, and asthma, as
susceptible subpopulations (U.S. EPA 2003,
2004a).
Further expansion of this mandate to
include genetically susceptible subpopulations
is recognized under the Interim Policy on
Genomics, which notes “the promise [of
genomics information] to identify variability
and susceptibilities in individuals from exposed
populations” (U.S. EPA 2002c). Provided that
genetic factors regulate multiple aspects of
asthma progression, researchers might ulti-
mately differentiate between genetically pre-
disposed asthmatic individuals to identify
those most susceptible to PM exposure.
Adverse effects. The CAA also seeks to
identify and protect citizens from “adverse
effects” caused by air pollution exposure. The
PM staff paper’s human health risk assessment
establishes a working definition for adverse
effects, with three types identiﬁed for consid-
eration in the NAAQS process: a) mortality—
nonaccidental total due to both cardiovascular
and respiratory causes; b) morbidity—hospital
admissions for cardiovascular and respiratory
causes; and c) symptomatic—increased respi-
ratory symptoms (U.S. EPA 2003). These are
adverse effects measured most consistently
in epidemiologic PM exposure studies.
Beyond this deﬁnition, the statutory language
leaves room for interpretation that invites
inclusion of any and all adverse biologic
effects, including those identiﬁed with genetic
information (American Thoracic Society
2000; Marchant 2002).
The Interim Policy on Genomics notes that
“genomics methodologies are expected to pro-
vide valuable insights for considering how
environmental stressors affect . . . how changes
in gene expression may relate to adverse
effects” (U.S. EPA 2002c). Genetic biomark-
ers can include biomarkers of susceptibility, as
shown in Table 1, as well as indicate subclini-
cal precursors to adverse effects as provided in
genomic RNA microarray studies showing
changes in gene expression proﬁles. The U.S.
EPA has historically considered subclinical
events as legitimate indicators of health effects;
for example, elevations in molecular biomark-
ers for exposure were used as evidence of
impaired biologic function in setting the 1978
NAAQS for lead (Marchant 2002). Genomic
biomarkers promise to provide a substantial
increase in quantifiable data that directly
deﬁne adverse effects.
Risk assessment process. The PM staff
paper details the risk assessment process used
in setting NAAQS. The current draft PM staff
paper focuses on epidemiologic studies, rely-
ing solely on relative risk metrics from daily
time-series population studies, while excluding
personal exposure and risk data (U.S. EPA
2003). Studies based on daily measures pre-
sent some challenges in the estimation of long-
term exposure and risk.
To address this gap in applicable available
data, the U.S. EPA performs sensitivity analy-
ses on key assumptions in the risk assessment.
For example, sensitivity analyses targeting
variation in concentration response, including
lag time in presentation of exposure-related
health effects, long-term exposure effects, and
hypothetical thresholds for PM concentration
response, are performed. The current PM
staff paper states: “There are, of course, sev-
eral other signiﬁcant uncertainties in the risk
assessment. . . . If there were sufﬁcient infor-
mation to characterize these sources of uncer-
tainty quantitatively, they could be included
in a Monte Carlo analysis to produce confi-
dence intervals that more accurately reﬂect all
sources of uncertainty” (U.S. EPA 2003).
Genetic information could be used to
improve sensitivity analyses. In fact, the U.S.
EPA tacitly approves the immediate use of
genetic information in risk-based regulation;
however, a number of barriers are evident. The
Interim Policy on Genomics states that “while
genomics data may be considered in decision
making at this time, these data alone are insuf-
ﬁcient as a basis for decisions” and will be con-
sidered only on “a case-by-case basis” (U.S.
EPA 2002c). Consequently, the U.S. EPA
remains limited by a lack of reliable genomic
data for informing decisions and effectively
constructing sensitivity analyses. Successful
inclusion would require findings based on
exposure response in geographically or nation-
ally representative epidemiologic models, with
reproducible data on genetic responses.
Regulatory health science relevant to
asthma. Asthma afflicts a significant and
increasing fraction of the U.S. population and
is the primary chronic disease in children.
The CDC reports that 21.9 million (10.6%)
adults suffer from clinically diagnosed asthma
at some point in their lifetime (CDC 2005).
Children are disproportionately likely to suf-
fer asthma, with 8.9 million (12.2%) experi-
encing the onset of asthma before the age of
18. In 2002, asthmatics accounted for 13.9
million hospital outpatient visits, 1.9 million
emergency department visits, 484,000 hospi-
talizations, and 4,261 deaths (CDC 2005).
The direct and indirect costs of the disease are
substantial, amounting to $12.7 billion in
1998 (Weiss and Sullivan 2001).
Asthma pathogenesis and progression
are a multifactorial process in which social,
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Table 1. Examples of genetic and biologic factors contributing to asthma disease progression.
Allelic frequency Estimated recessive
Genetic Hypothesized physiologic in population impact on asthma
Health effects biomarkers effect/phenotype Polymorphism (OR or RR) (OR or RR)
Environmental Allergic sensitization IL-4 TH2 development (antigen mediated) –590 C/T 0.17–0.80a,b 1.02–1.32a
sensitization IL-13 Increased IgE secretion –1111 T 0.21c 2.0d
Development Inﬂammation and tissue damage TNF-α Enhanced inﬂammatory response –308 G/A 0.22–0.30e 1.58–3.16e
β2ADR Damage smooth muscle Gly 16 0.376f 1.77–3.03f
Disease Asthma severity IL-13 AHR, mucus production, ﬁbrosis –1111 T 0.21c 2.0d
Bronchospasm IL-4 TH2 cell development –590 C/T 0.17–0.80a,b 1.02–1.32a
Airway hyperreactivity FcεRI-β IgE receptor, bronchial hyperresponsiveness 237 G 0.03–0.16b 2.3b
Mucus secretion β2ADR Bronchoconstriction, airway hyperreactivity Gly 16 0.376f 1.77–3.03f
Matrix remodeling IL-4R Bronchial hyperresponsiveness S 478 P 0.07–0.16a,g 0.86–1.13a
Abbreviations: OR, odds ratio; RR, relative risk; these are presented as single values or ranges, respectively. These candidate genetic biomarkers are characterized by their roles in allergic
sensitization, inﬂammation, and tissue damage and/or disease symptomology. The genetic biomarkers were selected using criteria speciﬁc to regulatory health science. The IL-13 promoter
polymorphism positions –1024 C/T, –1111 T, and –1055 T all have been shown to be identical using genetic analysis (Hummelshoj et al. 2003). We refer to this position as –1111 T-allele. Table
adapted from Bracken et al. (2002) and Leikauf (2002).
aLee et al. (2004). bZhu et al. (2000). cHoward et al. (2001). dHummelshoj et al. (2003). eWitte et al. (2002). fLitonjua et al. (2004). gHoward et al. (2002).environmental, and genetic factors interact.
Health scientists and clinicians deﬁne asthma
through observed adverse health effects corre-
sponding to airway inflammation, obstruc-
tion, and remodeling [National Institutes of
Health (NIH) 2003]. Occurring along a con-
tinuum, symptoms and reversibility vary
among diagnosed individuals from mild to
severe and are quantiﬁable by a range of bio-
logic and clinical indicators (NIH 2003).
Asthma may be described as occurring in
three stages—environmental sensitization,
development, and disease—which appear in
the left column of Figure 2 (Leikauf 2002).
Each stage is associated with a set of biologic
indicators, detailed in the middle section of
Figure 2. Given its complexity, researchers
identify asthma through multiple health end
points, including clinical diagnosis, presence
of high immunoglobulin (IgE) concentrations,
and changes in lung capacity. For this reason,
we place a high value on consistent use of
clearly defined and quantifiable health end
points for identifying asthmatics in our assess-
ment. We consider those end points for the
“disease” stage as the best available indicators
meeting our evaluation criteria: reversible
bronchospasms, airway hyperreactivity, mucus
secretion, and matrix remodeling. According
to the public health paradigm presented in
Figure 2 (right), exposure to a toxicant may
trigger a chain of biologic events that may ulti-
mately lead to disease (Decaprio 1997; NRC
1994; Sexton et al. 1995).
Along all the stages of disease progression,
scientists measure adverse effects associated
with asthma through exposure/effect biomark-
ers, such as cytokine levels or changes in lung
function. These are direct measurements indi-
cating internal dose and biologic response.
Additionally, susceptibility/genetic biomarkers
measure and/or predict predisposition to these
responses. Genetic biomarkers, such as up-reg-
ulation of genes, can provide quantifiable
measures of exposure response in those predis-
posed to disease. Still, researchers continue to
face great difﬁculty in identifying the most rel-
evant genetic biomarkers for asthma. As a
complex genetic disorder, asthma has multiple
genetic loci, each contributing small to modest
effects on overall disease progression (Xu et al.
2001). Hakonarson and Wjst (2001) reviewed
> 150 linkage, association, and candidate gene
studies collectively and report approximately
500 asthma and atopy loci identified across
the genome, and additional gene identiﬁcation
continues to arise beyond these regions
(Cookson 2003; Hakonarson et al. 2002;
Holgate et al. 2003; Howard et al. 2003;
Vercelli 2003; Weiss and Raby 2004). Finally,
each gene may contain multiple single
nucleotide polymorphisms associated with
functionally different phenotypes.
To facilitate identiﬁcation of key asthma
candidate genes relevant to regulatory health
science, we adapted the following criteria:
1. The gene product must be relevant to the
pathophysiology of a clearly defined and
consistent phenotype.
2. Gene function must be associated with
exposure to a regulated pollutant or, at the
very least, to a disease progression process
known to be associated with exposure to
the chosen regulated pollutant.
3. The mutation must be functionally rele-
vant.
4. The magnitude of frequency of occurrence
in the population must be measured and
variation across populations (geography,
race) must be considered.
5. There must be a high magnitude of associ-
ation (i.e., preferably relative risk > 1.5) to
an adverse health effect for the phenotype
of interest.
Table 1 presents an illustrative set of can-
didate genes selected in light of the above
criteria—interleukin (IL-4), IL-13, tumor
necrosis factor-α (TNF-α), β2-adrenergic
receptor (β2ADR), The β chain of the high
affinity receptor for IgE, FcεRI-β, and IL-4
receptor (IL-4R). The table’s columns repre-
sent the significant variables that asthma
genetics research must address, in the form of
the criteria outlined above. These columns
contain the estimated relative risk of asthma
associated with each polymorphism, based on
studies comparing response between asthmat-
ics and nonasthmatics and the hypothesized
roles of the genes in asthma disease progres-
sion. The frequency in the population is also
included. Not all candidate genes meet all of
the above criteria.
It is important to note what is missing
from Table 1. Because asthma research gener-
ating relative risks associated with speciﬁc poly-
morphisms and disease is still in its nascent
stages, with many inconsistent results, none of
these studies applies strictly to criterion 2 in
that none relates directly to PM exposure. Still,
Table 1 serves as an exemplary initial set of
polymorphisms that generically apply to most
air pollutants with known exacerbation of an
associated adverse health effect. As research
studies look more speciﬁcally at the effect of
individual pollutants, a unique set of candidate
genes and polymorphisms is expected for each
pollutant.
We note that not all of the listed polymor-
phisms meet the relative risk baseline of 1.5
(criterion 5), because of the lack of reﬁnement
in association studies to date. Table 1 instead
highlights relatively more robust studies using
consistent phenotype and where polymor-
phisms show positive associations and fairly
high frequencies in the population. The sub-
stantial variability in research associated with
complete assessment of all candidate genes and
their respective polymorphisms is not included.
This variability is a result of inconsistencies in
the analytical methods, varied definitions of
phenotype, frequent lack of replication, and
occasional lack of reported allelic frequencies
and/or relative risks.
There are indications that one would ﬁnd,
in future studies of susceptible cohorts,
increased relative risk of asthma based on gene–
environment and gene–gene interactions. Two
initial investigations suggest an increased rela-
tive risk from gene–gene interactions (Howard
et al. 2002; Lee et al. 2004). These studies
show that two cytokines, IL-4 and IL-13,
interact with their shared receptor, IL-4R, to
increase the relative risk for asthma from < 2 to
as high as 3.54 and 4.87, respectively, in
Kramer et al.
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Figure 2. Asthma health effects and disease progression along the public health paradigm as they relate to
environmental triggers and exposures. Adapted from Leikauf (2002), NIH (1997), and Sexton et al. (1995).
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2004).
Current Research Agendas
Concerning PM, Asthma, and
Genetics
As scientific understanding of the health
effects from PM exposure improves, the U.S.
EPA is required to ensure that the research
necessary to protect asthmatics continues to
progress. Section 103 of the 1990 CAAA
mandates that the U.S. EPA establish, coordi-
nate, conduct, and fund collaborative research
(Figure 1, left column) (U.S. Clean Air Act
Amendments 1990). Under an ideal applica-
tion of this mandate, U.S. EPA administrators
and research scientists would systematically
identify and fund critical research, which
would then serve as the basis for improving
regulatory standards under the two-way feed-
back loop of the risk assessment/risk manage-
ment paradigm.
PM exposure and health risk have been key
regulatory foci in recent years (see Table 2).
In 1997, Congress commissioned a National
Academy of Science (NAS) committee on PM
research and allocated nearly double the U.S.
EPA’s requested PM research funding—total-
ing $49.6 million in ﬁscal year (FY) 1998 and
$368 million between FY 1998 and FY 2003
(NRC 2004). The FY 1998 funding allowed
the U.S. EPA to establish the ﬁve university-
based PM centers and the National Environ-
mental Respiratory Center.
Since 1998, the NAS committee has
issued four substantial documents on PM
research needs and developments. Among the
top 10 research priorities cited, exposure of
susceptible subpopulations and the increased
risk for adverse health effects to these sub-
populations are identified as warranting sig-
niﬁcant resource backing (NRC 1998, 1999,
2001, 2004). The current PM criteria docu-
ment contains a toxicology subsection titled
“Genetic Susceptibility to Inhaled Particles
and Their Constituents” (U.S. EPA 2004a).
The current PM staff paper states that
“genetic susceptibility may play a role in dif-
ferential responses to inhaled particles across a
population” (U.S. EPA 2003). Still, the risk
assessment process for PM NAAQS remains
focused on epidemiologic research, particu-
larly time-series and case–control exposure
studies. Without additional research on
asthma genetics, the opportunity to account
for genetic susceptibility in the standard set-
ting process will not be realized.
The research strategies and directions of an
increasing group of government agencies pre-
sent priorities and identify decision options en
route to policy making that accounts for
asthma genetics (Table 2). Many also include
a multiyear funding allocation plan. For exam-
ple, asthma genetics is high on the priority list
of both the U.S. EPA’s Asthma Research
Strategy and the DHHS/NIH’s Action against
Asthma program (U.S. DHHS 2000; U.S.
EPA 2002a). Working groups commissioned
by governmental agencies, for example, the
CDC, continue to stress their commitment to
developing research on asthma genetics
(Center for Genomics and Public Health
2004; Cunningham et al. 2003; Henry et al.
2002). Commitments such as this one
promise the future development of air pollu-
tion exposure and risk assessments with regu-
latory relevance. Unfortunately, existing
research strategies fail to speciﬁcally promote
genetic susceptibility studies related to PM
exposure at this time.
Conclusions and
Recommendations
This case study contributes an in-depth
exploration of the potential role for genetic
information in the regulatory framework
under the CAA, speciﬁcally, in the process for
developing the PM NAAQS. In this com-
mentary, we develop the criteria by which one
would select candidate genes relevant to regu-
latory health science, identify a speciﬁc statute
(CAA) and key sections (103, 108, 112)
where genetic information should be consid-
ered, and identify opportunities to improve
decision making by incorporating informa-
tion on genetic variability.
We propose criteria for selecting candidate
genes to direct research on the etiology of
asthma and its relevance to regulatory
policy. Although we target PM and asthma,
the discussion should be viewed more gener-
ally, because genetic information can sub-
stantially improve risk assessment on any
environmental contaminant where genetic
predisposition influences the risk of adverse
health effects to identifiable subgroups. In a
subsequent analysis (Cullen AC, Kramer CB,
Faustman E, unpublished data), we extend this
analysis to encompass an evaluation of genetic
information in a decision analytic framework.
The present analysis further illustrates the
multifactorial considerations necessary for
devising adequate epidemiologic studies on
asthma genetics. The establishment of guide-
lines for genetic research with regulatory rele-
vance is imperative, given research trends in
the study of complex disease. Recent analyses
point out the imprecise replication of genetic
association studies (Hirschhorn et al. 2002;
Ioannidis et al. 2001; Merikangas and Risch
2003). Hirschhorn et al. (2002) reviewed 166
association studies and discovered a high level
of consistent reproduction in only six poly-
morphisms across multiple diseases. Ioannidis
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Table 2. Government agencies’ research strategies for addressing asthma genetic research.
Agency Publication (date) Example references to asthma genetics
U.S. EPA
Asthma Research Strategy “[Asthma] has a deﬁnite genetic component” (p. 1)
(U.S. EPA 2002a) “Susceptibility Factors” ranked second in research priority after
“Induction/Exacerbation” under “Prioritization of Research Areas” (p. 25)
“Genetic Susceptibility” ranked second in research priority after “Exposure
History” under “Susceptibility Factors” (p. 26)
Asthma toxics research strategy “Genetic variation . . . deﬁne additional sensitive subpopulations” (p. 48)
(U.S. EPA 2002b)
PM criteria document Toxicology subsection: “Genetic Susceptibility to Inhaled Particles and
(October 2004; Constituents” (sec. 7.5.2)
U.S. EPA 2004a) Integrative Synthesis subsection, under Potentially Susceptible and
Vulnerable Subpopulations, “Genetic Susceptibility (sec. 9.2.4.3)
PM staff paper “[A] number of new [toxicologic] studies . . . have suggested that genetic
(draft, August 2003; susceptibility may play a role in differential responses to
U.S. EPA 2003) inhaled particles across a population” (p. 3-67)
NAS
Research Priorities for “[G]ene micro-array techniques are being used for studies of air pollutants
Airborne Particulate Matter, even though determination of the most important genes, the roles of the
Vols. 1–4 (NRC 1998, 1999, genes and the best way to evaluate the huge amount of resulting data is
2001, 2004) still being resolved” (p. 114)
Clearing the Air: Asthma and “As early as the 1920s, studies demonstrated that a familial pre-disposition
Indoor Air Exposures to asthma existed, suggesting that genetics may play a role . . . however
(Institute of Medicine 2000) it explains only 30–80% of the asthma risk” (p. 28)
“Furthermore, the interaction of different environment exposures with
genetic susceptibilities must be elucidated” (p. 407)
DHHS
Action against Asthma Research Priority Area One: determine the causes of asthma and develop
(U.S. DHHS 2000) interventions to prevent its onset
“[A] major focus of research at several NIH institutes is on
gene-environment interactions, and includes a genome-wide search as
part of the Environmental Genome Project to identify genes that confer
susceptibility to asthma” (p. 16)
Urgent needs: primary prevention research (p. 16), study gene–environment
interactions and links to characteristics of asthmaKramer et al.
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et al. (2001) report similar results. These
studies cite a range of complications that
could be addressed by the development of
appropriate guidelines. Despite these chal-
lenges, Merikangas and Risch (2003) support
expansive research in molecular genetics, pro-
viding it is prioritized. Asthma genetics war-
rants a high-priority designation in the
national research agenda given its association
with factors beyond the exposed individual’s
control and the strict health basis of criteria
pollutant standard setting under the CAA.
As the U.S. EPA prepares to develop guid-
ance on the inclusion of genomics information
in risk assessment and decision making, we
propose the following action items to encour-
age the pursuit of asthma genetics research
solidly grounded in regulatory relevance:
• Fund research that specifically clarifies the
role of genetic susceptibility factors in air
pollution exposure. Although scientists con-
tinue to explore the role of genetics in
asthma etiology, the U.S. EPA must ensure
that epidemiologic and toxicologic studies
are designed to provide a strong basis for this
line of inquiry. Genetic information will
become relevant to regulatory policy only
with a solidly focused strategy.
• Fund longitudinal research with the aim of
clarifying the complexity of air pollution
effects over time and allowing for more
complete evaluation of genetic biomarkers
of susceptibility related to early adverse bio-
logic effects.
• Develop strategies for the incorporation of
genomic data in risk management methods.
The Interim Policy on Genomics states, “EPA
must understand how to develop and use
the research tools made possible from
genomics and understand the appropriate
uses of genomics data to inform Agency
decisions” (U.S. EPA 2002c). The policy
cites the need to increase internal infrastruc-
ture, apply improved information technolo-
gies to analyze genomic data, and expand
the capacity of computational toxicology
into the future. Although all of these tools
currently exist in a basic form, the U.S. EPA
should augment them to meet their own
needs as well as provide access to other indi-
viduals and organizations that will collabo-
rate in this endeavor.
• Cooperate with other agencies on integra-
tion of research strategies. As mandated in
Title I, section 103, of the CAAA (U.S.
Clean Air Act Amendments 1990), the U.S.
EPA must develop clear guidelines and
objectives for interagency research and
funding. Collaboration can ensure large
population studies essential to genetic epi-
demiology, along with the development of
widely accessible genetic databases. Without
proper collaboration between U.S. EPA and
other federal agencies, government-funded
research projects may not produce popula-
tion genetic science optimally relevant to
regulatory policy, and/or future research
may duplicate efforts already underway.
• Define validity of genetic biomarkers in
measuring adverse health effects. Given the
increased use and understanding of how bio-
markers work as indicators for disease pro-
gression along the public health paradigm,
the U.S. EPA should address the applicabil-
ity of biomarkers for exposure and suscepti-
bility (Decaprio 1997; Sexton and Adgate
1999). As the technology to quantify bio-
markers becomes cheaper, easier, and more
reliable, these indicators can be applied on a
population scale (Decaprio 1997). The U.S.
EPA should state the relevance of these
biomarkers as indicators of adverse health
effects to guide research and avoid litigation.
• Address ethical, legal, and social complexity.
Many ethical and social considerations per-
taining to genetic information currently lack
legal interpretation or guidance. The U.S.
EPA and partner agencies must assure the
public that scientists will respect the special
status of genetic information and use it ethi-
cally, so as not to invade privacy or improp-
erly communicate risks. As suggested in the
Interim Policy on Genomics, the U.S. EPA
should be proactive in the implementation of
guidelines for the use of genetic information
(U.S. EPA 2002c, 2004b).
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